Moreover, the overexpression of receptor tyrosine kinases (RTKs), such as EGFR, provides melanoma cells with alternative proliferative signals that enable them to circumvent the inhibitory effects of BRAF and MEK inhibitors (Gross et al., 2015; Zhong et al., 2022). Here, BRAF is linked to melanoma.